Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.51 |
| ▸ | WNT3A | P56704 | 4/20 | 0.51 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1492634 | 0.98 | RXRA (0.53) | RXRARXRBDYRK1APSEN1PSEN2 | |
| Dimethylamine SCHEMBL7231517 | 0.95 | PSEN1 (0.51) | RXRARXRBDYRK1APSEN1PSEN2 | |
| SCHEMBL18708472 | 0.83 | RAB9A (0.60) | RXRARXRB | |
| SCHEMBL14072799 | 0.83 | KMO (0.58) | RXRARXRBPSEN1PSEN2APH1B | |
| SCHEMBL30393655 | 0.83 | KMO (0.58) | RXRARXRBPSEN1PSEN2APH1B | |
| SCHEMBL6748946 | 0.81 | LOXL2 (0.57) | RXRARXRBMKNK1MKNK2 | |
| SCHEMBL28284992 | 0.81 | KDM4E (0.66) | RXRARXRBGRIK1GRIK2GRIK3 | |
| SCHEMBL30899157 | 0.81 | LOXL2 (0.57) | RXRARXRBMKNK1MKNK2 | |
| SCHEMBL1492671 | 0.81 | DYRK1A (0.58) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4894953 | 0.80 | LOXL2 (0.56) | RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| CN-1745071-A | Novel ethylenediamine derivative | DAIICHI SEIYAKU CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| CN-1220682-C | Heterocyclic derivatives which inhibit factor Xa | ZENECA LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| CN-1278793-A | Sulfonyl derivatives | DAIICHI SEIYAKU CO (JP) | 2001-01-03 | — | — | CN | disclosed |
| CN-1260781-A | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | CN | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| CN-1235597-A | Heterocycle derivatives inhibiting factor Xa | ZENECA LTD (GB) | 1999-11-17 | — | — | CN | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | RXRA 2631/4885RXRB 2366/4885DYRK1A 2209/4885 |
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | RXRA 2104/4885RXRB 2653/4885DYRK1A 3549/4885 |
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | RXRA 415/4885RXRB 438/4885DYRK1A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.